drugset / Trial / NCT03343613
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).
Timeline
- Start
- 2017-11-17
- Primary completion
- 2020-02-07
- Completion
- 2020-05-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LODAPOLIMAB | Monoclonal antibody | — | Intravenous |
| Subject | LY3381916 | Small molecule | — | Oral |